v3.26.1
Fair Value of financial assets and liabilities - Summary of movement of financial assets and liabilities accounted for at fair values at level 3 (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Other investments    
Balance at the beginning € 1,912,502  
Balance at the end 1,713,945 € 1,912,502
Level 3 | Contingent consideration    
Contingent consideration    
Balance at the beginning   (311)
Disposal   311
Level 3 | Equity instruments and other financial assets    
Other investments    
Balance at the beginning 21,909 40,328
Additions 7,259 11,749
Disposal (848)  
Transfer from Level 2 to Level 3   9,543
Transfer from Level 3 to Level 2 (329) (6,750)
Fair value change through P&L (2,974) (32,161)
Dividends received (1,053)  
Conversion of loans to investments in associates and joint ventures   (800)
Balance at the end 23,965 21,909
Level 3 | Aurobac Therapeutics SAS    
Other investments    
Additions 2,500  
Level 3 | Mission Bio Capital    
Other investments    
Additions 1,802 1,390
Dividends received (1,053)  
Level 3 | Carrick Therapeutics Ltd    
Other investments    
Disposal (848)  
Level 3 | Minority investments    
Other investments    
Transfer from Level 3 to Level 2 (329)  
Level 3 | Curie Bio Seed Fund I    
Other investments    
Fair value change through P&L (1,140) € 1,518
Level 3 | Quantro Therapeutics GmbH    
Other investments    
Fair value change through P&L € (2,127)